Latest News

FDA Type A Meeting Requested to Discuss SGX301 in Early-Stage CTCL
FDA Type A Meeting Requested to Discuss SGX301 in Early-Stage CTCL

March 10th 2023

Soligenix has requested a Type A meeting with the FDA to get clarity around the item needed to complete the new drug application of SGX301 for patients with early-stage cutaneous T-cell lymphoma.

FDA’s ODAC Votes for Polatuzumab Plus R-CHP for Previously Untreated DLBCL
FDA’s ODAC Votes for Polatuzumab Plus R-CHP for Previously Untreated DLBCL

March 9th 2023

New Solutions Continue to Show Up in the Lymphoma Treatment Landscape
New Solutions Continue to Show Up in the Lymphoma Treatment Landscape

March 9th 2023

FDA Approves Nelarabine Injection for the Treatment of T-ALL and T-LBL
FDA Approves Nelarabine Injection for the Treatment of T-ALL and T-LBL

March 7th 2023

Discussing Current and Potential Expansions to the Lymphoma Treatment Landscape
Discussing Current and Potential Expansions to the Lymphoma Treatment Landscape

March 2nd 2023

Video Series
Video Interviews
Podcasts

More News